Canagliflozin Hemihydrate: SGLT2 Inhibitor for Glucose Metabolism Research

Principle Overview: Precise SGLT2 Inhibition in Diabetes and Metabolic Research

Canagliflozin hemihydrate (SKU: C6434) is a highly pure, research-grade small molecule SGLT2 inhibitor designed for the rigorous demands of glucose metabolism research and diabetes mellitus research. Its mechanism—selective inhibition of the sodium-glucose co-transporter 2 (SGLT2)—targets renal glucose reabsorption, resulting in increased urinary glucose excretion and lowered systemic glucose. This specificity enables detailed mechanistic studies of the glucose homeostasis pathway, distinguishing it from compounds affecting broader metabolic or signaling cascades such as mTOR inhibitors.

Canagliflozin hemihydrate, with a chemical formula of C24H26FO5.5S and a molecular weight of 453.52, is characterized by high solubility in organic solvents (≥40.2 mg/mL in ethanol, ≥83.4 mg/mL in DMSO) and minimal water solubility, supporting flexible experimental designs. Its purity (≥98%, HPLC and NMR verified) ensures reproducible results across diverse metabolic disorder research workflows.

Step-by-Step Workflow: Experimental Setup and Protocol Enhancements

1. Compound Preparation and Storage

• Solubility: Dissolve Canagliflozin hemihydrate in DMSO or ethanol to achieve stock concentrations suitable for in vitro or in vivo dosing. For example, a 10 mM stock in DMSO (4.53 mg/mL) is commonly prepared for cell-based assays.
• Stability: Store the powder at -20°C. Prepare fresh working solutions immediately before use; avoid long-term storage of solutions to prevent degradation and loss of efficacy.
• Shipping: Blue ice shipment ensures compound integrity for research applications.

2. In Vitro Applications: Glucose Uptake and SGLT2 Activity Assays

• Cell Model Selection: Employ renal proximal tubule epithelial cells (e.g., HK-2, LLC-PK1) or engineered lines overexpressing human SGLT2 for direct mechanistic studies.
• Assay Setup: Incubate cells with labeled glucose (e.g., [¹⁴C]-glucose) in the presence or absence of Canagliflozin hemihydrate. Typical concentrations range from 10 nM to 10 μM, with dose-response curves revealing IC₅₀ values in the low nanomolar range for SGLT2 inhibition.
• Readouts: Quantify glucose uptake using scintillation counting or colorimetric glucose oxidase assays. Expect >90% inhibition of SGLT2-mediated glucose transport at concentrations ≥1 μM.

3. In Vivo Studies: Rodent Models of Diabetes Mellitus

• Dosing: Dissolve Canagliflozin hemihydrate in a vehicle compatible with oral gavage (e.g., 0.5% methylcellulose with DMSO). Standard dosing regimens are 5–30 mg/kg/day, based on preclinical diabetes models.
• Endpoints: Measure fasting and postprandial blood glucose, urinary glucose excretion, and insulin levels. A 7-day treatment often yields a 30–50% reduction in fasting glucose in diabetic rodents (data summarized from preclinical studies in referenced literature).
• Controls: Include vehicle-treated and positive control (e.g., dapagliflozin or empagliflozin) groups to benchmark effects within the canagliflozin drug class.

4. Integration with Multi-Omics and Systems Biology

• Combine SGLT2 inhibition with transcriptomic or metabolomic profiling to dissect downstream effects on glucose and lipid metabolism.
• Use Canagliflozin hemihydrate as a tool compound in CRISPR-based gene knockout models to delineate SGLT2-specific versus compensatory pathways.

Advanced Applications and Comparative Advantages

Canagliflozin hemihydrate’s selectivity and high purity make it an ideal probe for:

• Dissecting glucose homeostasis: Its precise action on SGLT2, without direct effects on mTOR or other kinases, allows unambiguous attribution of phenotypes to renal glucose reabsorption inhibition. This was underscored by recent yeast-based screening studies that found no evidence for mTOR pathway modulation by Canagliflozin, confirming its mechanistic specificity.
• Benchmarking SGLT2 inhibitor class effects: Comparative studies (see "Canagliflozin Hemihydrate in SGLT2 Inhibitor Research") highlight how Canagliflozin hemihydrate enables head-to-head analyses with other SGLT2 inhibitors, illuminating differences in off-target profiles and metabolic impact.
• Metabolic disorder modeling: Its robust, dose-dependent efficacy in rodent models of diabetes and obesity supports its use in pathway dissection, drug combination studies, and phenotypic screening for metabolic syndrome interventions.

Importantly, Canagliflozin hemihydrate’s utility is not limited to classic glucose transport assays. As detailed in "Canagliflozin Hemihydrate: SGLT2 Inhibitor for Precision...", the compound is increasingly leveraged in integrative systems biology approaches, where its specificity enables clear mapping of downstream signaling and metabolic changes following SGLT2 blockade.

For researchers seeking technical comparisons or guidance on experimental design, "Canagliflozin Hemihydrate: Precision SGLT2 Inhibition for..." provides a complementary analysis, underscoring the product’s reliability for high-sensitivity mechanistic studies.

Troubleshooting & Optimization Tips

• Compound Solubility: If precipitation occurs during dilution, ensure the DMSO or ethanol stock is fully dissolved before adding to aqueous buffers. Pre-warm solutions to 37°C and vortex thoroughly.
• Assay Sensitivity: For low-abundance SGLT2 models, optimize cell density and incubation times. Consider increasing compound concentration incrementally (e.g., 10 nM to 10 μM) to establish a robust inhibition curve.
• Specificity Controls: To confirm SGLT2-specific effects, include SGLT1-expressing controls or use SGLT2-null cell lines. This is particularly important given potential off-target effects at supra-physiological concentrations.
• Batch-to-Batch Consistency: Confirm the lot-specific purity (≥98%) via HPLC or request a certificate of analysis from your supplier. Always document lot numbers in experimental records.
• Long-Term Stability: Avoid storing working solutions for more than 24 hours. Discard any unused diluted compound to prevent confounding degradation artifacts.
• Negative Screening Results: As shown in the mTOR inhibitor yeast screen, Canagliflozin hemihydrate does not inhibit mTOR/TOR pathways, clarifying its negative result in such screens and reinforcing its mechanistic specificity for SGLT2.

Future Outlook: Integration and Innovation in Metabolic Research

Canagliflozin hemihydrate’s role as a reference-standard SGLT2 inhibitor positions it at the forefront of next-generation metabolic disorder research. With expanding interest in combinatorial therapies and precision medicine, its use in synergy studies (e.g., with GLP-1 receptor agonists or insulin sensitizers) is anticipated to grow. Furthermore, adaptation of high-throughput screening platforms, as described in the recent mTOR inhibitor discovery study, could be leveraged to profile SGLT2 inhibitor off-target interactions, further refining their translational potential.

For researchers seeking robust, reproducible results in the study of glucose homeostasis and renal glucose reabsorption inhibition, Canagliflozin (hemihydrate) offers a validated, high-purity solution. As the field advances toward multi-omics integration and systems-level metabolic modeling, its mechanistic clarity and versatile research utility will remain indispensable.